|
IMVT Immunovant Inc 1764013 |
| Income Statement |
|
Net Income
|
2026-06-30
|
$-153,224,000.00 |
| Balance Sheet |
|
Current Assets
|
$851,178,000.00 |
|
Assets
|
$852,490,000.00 |
|
Current Liabilities
|
$117,102,000.00 |
|
Liabilities
|
$117,102,000.00 |
|
Equity
|
$735,388,000.00 |
|
Shares Out
|
206264878.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-124,405,000.00 |
|
Investing Cash Flow
|
$-8,000.00 |
| Market Analysis |
Market Cap
|
$9,147,847,339.30 |
|
Price
|
$44.35 |
|
BVPS
|
3.57 |
|
PB
|
12.42 |
|
EPS
|
-0.75 |
|
FCF
|
$-124,413,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:21 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:13 |
|
| Jan |
Feb |
Mar |
|
|
|
|
2026-02-06 |
-0.61 |
|
| Apr |
May |
Jun |
|
|
|
|
2026-05-20 |
-0.73 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-11 |
-0.71 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-10 |
-0.73 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view IMVT documents filed with the SEC.
IMVT Filings
Clear
